PDT Partners’s Adverum Biotechnologies ADVM Stock Holding History

PDT Partners’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,032	Closed	-$141K	–	755
2021 Q2	$141K	Sell	4,032 -190	-5%	-$10.2K	0.01%	744
2021 Q1	$416K	Sell	4,222 -321	-7%	-$38.5K	0.03%	540
2020 Q4	$492K	Buy	+4,543	New	+$562K	0.03%	452
2020 Q1	–	Sell	-13,820	Closed	-$1.59M	–	643
2019 Q4	$1.59M	Buy	+13,820	New	+$1.22M	0.1%	213
2018 Q4	–	Sell	-15,650	Closed	-$947K	–	460
2018 Q3	$947K	Sell	15,650 -5,310	-25%	-$298K	0.04%	315
2018 Q2	$1.11M	Sell	20,960 -17,610	-46%	-$1.06M	0.04%	318
2018 Q1	$2.24M	Buy	+38,570	New	+$2.4M	0.08%	261
2017 Q2	–	Sell	-3,455	Closed	-$93K	–	510
2017 Q1	$93K	Hold	3,455	–	–	﹤0.01%	462
2016 Q4	$100K	Sell	3,455 -570	-14%	-$18.6K	0.01%	487
2016 Q3	$165K	Sell	4,025 -640	-14%	-$24.3K	0.01%	446
2016 Q2	$147K	Buy	+4,665	New	+$211K	0.01%	415
2015 Q3	–	Sell	-4,881	Closed	-$793K	–	1230
2015 Q2	$793K	Buy	+4,881	New	+$1.65M	0.02%	809

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PDT Partners's ADVM Position: Q3 2021 in Review

PDT Partners sold out of Adverum Biotechnologies (ADVM) in Q3 2021, closing a stake of 4,032 shares — an estimated $141K sold.

PDT Partners first reported a position in ADVM in Q2 2015 and held it in 12 quarters. The position peaked at $2.24M in Q1 2018. 110 funds tracked by Wall St. Rank hold ADVM as of Q3 2021.

PDT Partners reported no remaining Adverum Biotechnologies position as of Q3 2021 after selling out during the quarter.
PDT Partners sold 4,032 Adverum Biotechnologies shares in Q3 2021, an estimated $141K.
PDT Partners first reported a position in Adverum Biotechnologies in Q2 2015 and held it in 12 quarters.
PDT Partners's Adverum Biotechnologies position peaked at $2.24M in Q1 2018.
110 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.